MCID: DRG016
MIFTS: 24

Drug Induced Dyskinesia

Categories: Rare diseases

Aliases & Classifications for Drug Induced Dyskinesia

MalaCards integrated aliases for Drug Induced Dyskinesia:

Name: Drug Induced Dyskinesia 52
Dyskinesia, Drug Induced 52
Dyskinesia, Drug-Induced 71
Drug-Induced Dyskinesia 17

Classifications:



External Ids:

UMLS 71 C0013386

Summaries for Drug Induced Dyskinesia

NIH Rare Diseases : 52 Drug induced dyskinesia is an involuntary movement disorder. Signs and symptoms include repetitive and irregular motions of the mouth, face, limbs and/or trunk. Treatment with antipsychotic drugs and levodopa (commonly used to treat Parkinson disease ) are well recognized causes of drug-induced dyskinesia. Dyskinesia develops in around 40% of people with Parkinson's disease who have been on levodopa treatment for four to six years. Tardive dyskinesia is a severe form of drug-induced dyskinesia due to antipsychotic treatments. Tardive dyskinesia develops in 5% of people per year of treatment.

MalaCards based summary : Drug Induced Dyskinesia, also known as dyskinesia, drug induced, is related to tardive dyskinesia and chorea, childhood-onset, with psychomotor retardation, and has symptoms including ataxia, myoclonus and tremor. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and subthalamic nucleus.

Related Diseases for Drug Induced Dyskinesia

Diseases related to Drug Induced Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 10.2
2 chorea, childhood-onset, with psychomotor retardation 10.2
3 choreatic disease 10.2
4 dystonia 10.2
5 huntington disease 9.9
6 parkinson disease, late-onset 9.9
7 torticollis 9.9
8 neuronal intranuclear inclusion disease 9.9
9 focal dystonia 9.9
10 tic disorder 9.9
11 movement disease 9.9
12 speech disorder 9.9
13 pathologic nystagmus 9.9
14 athetosis 9.9
15 dysphagia 9.9
16 myoclonus 9.9
17 tremor 9.9

Graphical network of the top 20 diseases related to Drug Induced Dyskinesia:



Diseases related to Drug Induced Dyskinesia

Symptoms & Phenotypes for Drug Induced Dyskinesia

UMLS symptoms related to Drug Induced Dyskinesia:


ataxia, myoclonus, tremor, dystonia, athetosis, synkinesis

Drugs & Therapeutics for Drug Induced Dyskinesia

Drugs for Drug Induced Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Amantadine Approved Phase 4 768-94-5 2130
4
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
5 Serotonin Receptor Agonists Phase 4
6 Serotonin 5-HT1 Receptor Agonists Phase 4
7 Dopamine Agents Phase 4
8 Dopamine agonists Phase 4
9 Neurotransmitter Agents Phase 4
10 Antidepressive Agents Phase 4
11 Psychotropic Drugs Phase 4
12 Antiparkinson Agents Phase 4
13 Anti-Infective Agents Phase 4
14 Analgesics Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Antiviral Agents Phase 4
17 Neuroprotective Agents Phase 4
18 Monoamine Oxidase Inhibitors Phase 4
19 Protective Agents Phase 4
20
Piracetam Approved, Investigational Phase 3 7491-74-9
21
Levetiracetam Approved Phase 2 102767-28-2 441341
22
Topiramate Approved Phase 2 97240-79-4 5284627
23 Dihydroxyphenylalanine Phase 2
24 Antipsychotic Agents Phase 2
25 Anticonvulsants Phase 2
26 Hypoglycemic Agents Phase 2
27
Olanzapine Approved, Investigational Phase 1 132539-06-1 4585
28
Risperidone Approved, Investigational Phase 1 106266-06-2 5073
29 Dopamine Antagonists Phase 1
30 Gastrointestinal Agents Phase 1
31 Serotonin Uptake Inhibitors Phase 1
32 Quetiapine Fumarate Phase 1 111974-72-2
33 Antiemetics Phase 1
34
Serotonin Investigational, Nutraceutical Phase 1 50-67-9 5202
35
Lovastatin Approved, Investigational 75330-75-5 53232
36
Simvastatin Approved 79902-63-9 54454
37 Dihydromevinolin
38 Hydroxymethylglutaryl-CoA Reductase Inhibitors
39 L 647318

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study Unknown status NCT00837707 Phase 4 aripiprazole
2 Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
3 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
4 Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study Completed NCT00190008 Phase 3 piracetam
5 A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations Withdrawn NCT03987750 Phase 3 Safinamide Methanesulfonate 150mg;Safinamide Methanesulfonate 100mg;Safinamide Methanesulfonate matching placebo
6 An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years. Completed NCT00175955 Phase 2 Levetiracetam
7 An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Completed NCT01173731 Phase 2 AFQ056
8 A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia Completed NCT01092065 Phase 2 AFQ056 with L-dopa;Placebo
9 Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS) Completed NCT02657681 Phase 2
10 A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components Not yet recruiting NCT04377945 Phase 2 Part 1, JM-010 component Group A;Part 1, JM-010 component Group B;Part 1, JM-010 component Group C;Part 1, Placebo Group;Part 2, JM-010 combination Group A;Part 2, JM-010 combination Group B;Part 2, Placebo Group;Part 2, JM-010 component Group C
11 Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia Not yet recruiting NCT04147949 Phase 2 AV-101;Placebo
12 A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders Terminated NCT00686699 Phase 2 Preladenant;Placebo
13 Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Terminated NCT01789047 Phase 2 Topiramate;Placebo;Amantadine
14 Neuroleptic Induced Movement Disorders in Older Patients Completed NCT00255879 Phase 1 Quetiapine;Risperidone;Olanzapine
15 Targeting the Pre-supplementary Motor Area With Repetitive Transcranial Magnetic Stimulation to Alleviate Levodopa-induced Dyskinesia in Parkinson´s Disease Completed NCT03354455
16 Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins Active, not recruiting NCT04064294 Intravenous Infusion

Search NIH Clinical Center for Drug Induced Dyskinesia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alpha-Tocopherol Acetate
Amantadine
Amantadine Hydrochloride
d-alpha-Tocopheryl Acetate
dl-alpha tocopheryl acetate
Tocopherol Acetate
TOCOPHEROL,DL-ALPHA
Tocopherols
TOCOPHERYL ACID SUCCINATE
TOCOPHERYL ACID SUCCINATE,D-ALPHA
Vitamin E

Genetic Tests for Drug Induced Dyskinesia

Anatomical Context for Drug Induced Dyskinesia

MalaCards organs/tissues related to Drug Induced Dyskinesia:

40
Brain, Testes, Subthalamic Nucleus, Cortex, Globus Pallidus

Publications for Drug Induced Dyskinesia

Articles related to Drug Induced Dyskinesia:

(show top 50) (show all 91)
# Title Authors PMID Year
1
Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. 61
32459404 2020
2
Understanding Parkinson's disease and deep brain stimulation: Role of monkey models. 61
31871164 2019
3
Human Depotentiation following Induction of Spike Timing Dependent Plasticity. 61
29912149 2018
4
Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia. 61
29843253 2018
5
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment. 61
29304113 2018
6
D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats. 61
28667675 2017
7
[Effects of bilateral deep brain stimulation in the subthalamic nucleus using two methods of target structure verification]. 61
29265083 2017
8
[Unilateral posteroventral pallidotomy in the treatment of drug-induced dyskinesia in Parkinson's disease]. 61
29076470 2017
9
Benefits of subthalamic stimulation for elderly parkinsonian patients aged 70 years or older. 61
27494146 2016
10
Orofacial Movement Disorders. 61
27475514 2016
11
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. 61
27091214 2016
12
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. 61
27091215 2016
13
Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease. 61
26898686 2016
14
[The preliminary results of subthalamic nucleus stimulation after destructive surgery in Parkinson's disease]. 61
28139571 2016
15
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia. 61
26363150 2015
16
One-year Outcome of Bilateral Subthalamic Stimulation in Parkinson Disease: An Eastern Experience. 61
26072454 2015
17
Bilateral subthalamic stimulation for advanced Parkinson disease: early experience at an Eastern center. 61
25394741 2015
18
Safinamide: first global approval. 61
25851099 2015
19
[Pain fluctuations in Parkinson's disease]. 61
26525814 2015
20
[Pharmacotherapy accompanied by deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease]. 61
28635789 2015
21
Effect of hydro-alcoholic root extract of Plumbago zeylanica l alone and its combination with aqueous leaf extract of Camellia sinensis on haloperidol induced parkinsonism in wistar rats. 61
25206060 2014
22
Deep brain stimulation improves survival in severe Parkinson's disease. 61
23843542 2014
23
Adaptive gene regulation in the Striatum of RGS9-deficient mice. 61
24663062 2014
24
Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. 61
23632325 2013
25
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? 61
23514355 2013
26
New insights into the mechanism of drug-induced dyskinesia. 61
23593652 2013
27
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. 61
22569849 2012
28
Comprehensive treatment of Huntington disease and other choreic disorders. 61
22761268 2012
29
Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. 61
22093536 2011
30
Kinematic optimization of deep brain stimulation across multiple motor symptoms in Parkinson's disease. 61
21459111 2011
31
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat. 61
21220017 2011
32
Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats. 61
20628966 2011
33
Assessing drug-induced dyskinesia in the clinic, the laboratory and the natural environment of patients. 61
23939342 2011
34
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. 61
20310033 2010
35
Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. 61
20629123 2010
36
A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. 61
19726410 2010
37
Ziprasidone-related oculogyric crisis in an adult. 61
19717224 2009
38
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. 61
18307261 2008
39
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. 61
18417699 2008
40
Quantifying drug induced dyskinesia in Parkinson's disease patients using standardized videos. 61
19163023 2008
41
[Drug induced dyskinesia]. 61
17802711 2007
42
Deep brain stimulation in neurologic disorders. 61
17141550 2007
43
Bilateral subthalamotomy for advanced Parkinson disease. 61
17963922 2007
44
Modulation of human motor cortex excitability by single doses of amantadine. 61
16794570 2006
45
Parkinson's disease: diagnosis and treatment. 61
17186710 2006
46
Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. 61
16444668 2006
47
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. 61
15728856 2005
48
Unilateral stereotactic posteroventral globus pallidus internus pallidotomy for Parkinson's disease: surgical techniques and 2-year follow-up. 61
15754582 2005
49
The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease. 61
15200114 2004
50
Influence of age on iminodipropionitrile-induced vestibular and neurobehavioral toxicities in rats. 61
14620540 2003

Variations for Drug Induced Dyskinesia

Expression for Drug Induced Dyskinesia

Search GEO for disease gene expression data for Drug Induced Dyskinesia.

Pathways for Drug Induced Dyskinesia

GO Terms for Drug Induced Dyskinesia

Sources for Drug Induced Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....